



Eleison Announces the Issuance of New Patents for Glufosfamide and ILC

St. Petersburg, FL, December 11, 2015 -- Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, has announced the issuance of United States Patents, No. 9,205,098 and No. 9,107,824. No. 9,205,098 describes the treatment of cancer patients with the combination of chemotherapeutic agents Glufosfamide and gemcitabine. No. 9,107,824 describes the method and use of ILC (lipid-complexed cisplatin), via intraperitoneal administration, for the treatment of patients with cancer, such as ovarian cancer.

About Glufosfamide

Glufosfamide, a new chemical entity, is a third-generation alkylating agent designed for greater specificity and tumor uptake, with reduced systemic toxicities and side effects. Eleison is currently enrolling patients in a pivotal multi-national Phase III study of Glufosfamide as second-line therapy for patients with metastatic pancreatic cancer. For more information about this Phase III clinical trial, please visit <https://www.clinicaltrials.gov/ct2/show/NCT01954992?term=glufosfamide&rank=2>. Eleison possesses worldwide exclusive rights to Glufosfamide, and has entered into marketing and development agreements with partners in Asia.

About Pancreatic Cancer

Pancreatic cancer is the fourth leading cause of death by cancer in the United States. More than 46,000 Americans are diagnosed with pancreatic cancer annually, resulting in 40,000 deaths each year. There exist few effective therapeutic options to treat this disease, as five year survival rates are typically less than 5%.

About ILC

Eleison has an exclusive worldwide license to ILC, a novel, sustained release formulation of cisplatin in a nanoscale lipid-based complex administered via inhalation or intraperitoneally. ILC, when administered by inhalation, can deliver high levels of sustained release cisplatin targeted to the lung, with minimal or no systemic-related toxicities. Eleison recently completed a Phase II study of ILC in patients with bone cancer (osteosarcoma).

About Pediatric Osteosarcoma

In the U.S., 500 children and young adults are diagnosed with osteosarcoma each year, a type of bone cancer. Standard therapy includes a combination of surgery and chemotherapy, although 30-35% of patients will experience a recurrence, most often in the lungs and only in the lungs. The prognosis for relapsed patients with pulmonary metastases is particularly grim, with five year survival of less than 25%.

About Eleison Pharmaceuticals

Eleison's mission is to acquire, develop, and commercialize clinical stage drug candidates for "orphan" oncology indications, providing new hope for patients with rare life-threatening diseases. Eleison was founded in 2009 and is headquartered in St. Petersburg, FL.

Forward Looking Statements

Except for statements of historical fact, the statements in this news release are forward-looking statements, including statements regarding Eleison's product candidates, their uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Eleison's ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Eleison does not intend to update any forward-looking statement made in this news release.

COMPANY CONTACT: Eleison Pharmaceuticals LLC
Corporate Communications
263 13th Avenue South, Suite 375
St. Petersburg, FL 33701
tel: 215-554-3530 email: info@eleison-pharma.com